Search Results 1021-1030 of 25549 for treatment resistant depression
each treatment alone to improve pain, self-reported function, depression, and anxiety in patients with chronic low back pain and high negative affect. A ...
... resistant. No more than one prior line of therapy for platinum resistant disease. NOTE: Prior PARP inhibitor therapy is allowed. Measurable disease per ...
Cognitive behavioral therapy, self-efficacy, and depression in persons with chronic pain. ... Treatment outcomes after multidisciplinary pain rehabilitation with ...
The purpose of this Phase 1a/1b study of SC-003 in patients with platinum-resistant/refractory ovarian cancer is to characterize the safety and tolerability of ...
... treatment of drug refractory symptomatic paroxysmal atrial fibrillation. Participation eligibility. Participant eligibility includes age, gender, type and ...
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (how a drug moves within the body) and clinical activity of HH2853, an EZH1/ ...
... depression or anxiety; Joint or muscle pain; Heart ... treated in a hospital intensive care unit. ... The information you provide and any test results will help ...
Participation eligibility · NOTE: This patient population includes the following 3 categories of patients: · For the purposes of this study, refractory disease is ...
Participation eligibility. Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines ...
A Study to Assess Safety and Effectiveness of Venetoclax in Combination With Gilteritinib in Subjects With Relapsed/Refractory Acute Myeloid Leukemia. Print ...
Mayo Clinic does not endorse companies or products. Advertising revenue supports our not-for-profit mission.
Check out these best-sellers and special offers on books and newsletters from Mayo Clinic Press.
Make a gift before July 31 and it can go twice as far to fight cancer.